Search Within

Marissa Mattar

  1. "Qing Chang"
Formats
  1. Meeting Abstract (3)
  2. Journal Article (2)
Groups
  1. GSK Faculty (5)
  2. Sloan Kettering Institute Postdocs (5)
  3. Tow Center for Developmental Oncology (TCDO) (5)
  4. Department of Pathology and Laboratory Medicine (4)
  5. Human Oncology and Pathogenesis Program (4)
  6. Department of Medicine (2)

More Groups

People
  1. Elisa De Stanchina (5)
  2. Qing Chang (5)
  3. Inna Khodos (4)
  4. Marc Ladanyi (4)
  5. Romel Somwar (4)
  6. Yue christine Lu (2)

More People

Years
  1. 2023 (1)
  2. 2022 (4)
Publications
  1. European Journal of Cancer (1)
  2. Journal of Thoracic Oncology (1)
  3. Molecular Cell (1)
  4. Nature Cancer (1)
  5. Neuro-Oncology (1)
Publishers
  1. Elsevier Inc. (2)
  2. Cell Press (1)
  3. Nature Research (1)
  4. Oxford University Press (1)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
    Journal Article

    Miyazaki, I.; Odintsov, I.; Ishida, K.; Lui, A. J. W.; Kato, M.; Suzuki, T.; Zhang, T.; Wakayama, K.; Kurth, R. I.; Cheng, R.; more...
    Nature Cancer (2023)

    Fulltext@MSK | Save
  • Tractable patient-derived models for preclinical therapeutic studies of CNS metastases
    Meeting Abstract

    Vojnic, M.; Odintsov, I.; Offin, M. D.; Lui, A. J. W.; Khodos, I.; Chang, Q.; Mattar, M. S.; De Stanchina, E.; Ladanyi, M.; Somwar, R.
    Neuro-Oncology (2022)

    Fulltext@MSK | Save
  • Vepafestinib is effective in preclinical models of sarcomas with RET fusion including a brain metastasis model
    Meeting Abstract

    Odintsov, I.; Liu, A.; Khodos, I.; Chang, Q.; Giuliano, C.; Mattar, M.; Vojnic, M.; Bonifacio, A.; De Stanchina, E.; Lovati, E.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • TA0953/HM06, a novel RET-specific inhibitor effective in extracranial and CNS disease models of NSCLC with RETfusions
    Meeting Abstract

    Odintsov, I.; Lui, A. J. W.; Delasos, L.; Khodos, I.; Chang, Q.; Mattar, M. S.; Vojnic, M.; Lu, Y. C.; Kunte, S.; Bonifacio, A.; more...
    Journal of Thoracic Oncology (2022)

    Fulltext@MSK | Save
  • ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1
    Journal Article

    Su, W.; Mukherjee, R.; Yaeger, R.; Son, J.; Xu, J.; Na, N.; Timaul, N. M.; Hechtman, J.; Paroder, V.; Lin, M.; more...
    Molecular Cell (2022)

    Fulltext@MSK | Save